7 Deer Park Drive
About CytoSorbents, Inc.CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is CE Mark certified and is currently distributed in 37 countries around the world as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy.
Founders: Christian Steiner and Phillip Chan
CEO: Phillip Chan
Please click here for CytoSorbents job opportunities.
Tweets by CytoSorbents
365 articles with CytoSorbents, Inc.
CytoSorbents Corporation reported unaudited financial and operating results for the quarter ended March 31, 2022.
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany
CytoSorbents Corporation announced that the Company has been awarded a new preferred supplier agreement for CytoSorb® with the Asklepios Group.
A roundup of last week's top clinical trial updates and news.
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery
CytoSorbents Corporation announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb™-ATR Antithrombotic Removal System for intraoperative removal of apixaban and rivaroxaban during cardiothoracic surgery.
CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress
CytoSorbents Corporation announced that the Company will participate in the 10th EuroELSO Congress in London, UK being held May 4-6, 2022, one of the two major conferences for ECMO users worldwide.
CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2022 operating and financial results after the market close on May 3, 2022.
CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World
CytoSorbents Corporation announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence.
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program
CytoSorbents Corporation today announced that it has received approximately $740,000, net of transactions costs.
CytoSorbents Corporation announces the appointment of Ms. Jiny Kim, MBA to CytoSorbents' Board of Directors as a new independent director, effective immediately, for a term expiring at the Company's 2022 Annual Meeting, scheduled for June 7, 2022, at which time Ms. Kim is expected to stand for re-election.
CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM)
CytoSorbents Corporation announced that the Company will participate in the 41st International Symposium on Intensive Care and Emergency Medicine ( ISICEM 2022 ) Congress.
CytoSorbents Corporation reported audited financial and operating results for the quarter and year ended December 31, 2021 and provides its 2022 outlook.
CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2021 operating and financial results after the market close on March 8, 2022.
CytoSorbents Corporation announces management will participate in two upcoming virtual investor conferences.
First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock
CytoSorbents Corporation announced today that the first patient has been enrolled in the PROCYSS trial in Germany by Prof. Dr. Stefan Kluge, Director, Department of Intensive Care Medicine at the University Hospital Hamburg Eppendorf and lead investigator of the PROCYSS trial.
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology
CytoSorbents Corporation highlights a new publication in the peer-reviewed journal, Annals of Thoracic and Cardiovascular Surgery , entitled " Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations."
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
CytoSorbents Corporation issues a stockholder letter from its Chief Executive Officer, Dr. Phillip Chan, and announces preliminary unaudited fourth quarter 2021 and full year 2021 results ahead of filing its Form 10-K.
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular
CytoSorbents Corporation announces the appointment of Professor Daniel Wendt , MD, PhD, MHBA, FETCS as Vice President, Medical Affairs Cardiovascular commencing January 1, 2022.
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
CytoSorbents Corporation announces the publication of results from the Company's U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine.
CytoSorbents Corporation reports full financial and operating results for the quarter ended September 30, 2021.
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery
CytoSorbents Corporation announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb-ATR™ Antithrombotic Removal System for intraoperative removal of ticagrelor during cardiothoracic surgery.